NASDAQ:DNLI | News — Page 2 | Denali Therapeutics Inc.

DNLI News — Page 2

Official issuer or fund updates, exact SEC current reports, and large established publisher coverage, newest first. Every lawfully retained item remains in the corpus; each public page contains at most 100 rows. Headlines open the exact source; summaries are concise descriptions and not investment recommendations. Captured 2026-08-31.

DateTypePublisherHeadlineSummary
2017-12-12Current reportSEC filingDenali Therapeutics Inc. filed Form 8-KDenali Therapeutics Inc. filed Form 8-K covering items 5.03,7.01,9.01.